Newer TPO Receptor Agonists for Chronic ITP

Introduction And Disease Burden

Chronic immune thrombocytopenia (ITP) in children is defined as thrombocytopenia persisting beyond 12 months from diagnosis.
Incidence reaches 5 to 10 per 100,000 annually in India, with persistent or chronic forms comprising 20% to 30% of total pediatric ITP cases.
Chronic ITP causes significant morbidity, marked by persistent mucosal bleeding risk, reduced quality of life, high school absenteeism, and severe treatment-related anxiety.
First-line therapies, including systemic corticosteroids and intravenous immunoglobulin (IVIG), fail to achieve sustained remission in a significant proportion of patients, necessitating definitive second-line interventions.

Thrombopoietin receptor agonists (TPO-RAs) revolutionized chronic ITP management by directly stimulating megakaryopoiesis and accelerating platelet production without inducing generalized immunosuppression.
TPO-RAs are now universally preferred as second-line agents over historical modalities like rituximab or irreversible surgical splenectomy.
Early TPO-RA utilization preserves pediatric quality of life, minimizes the necessity for emergency rescue therapies, and supports normal somatic growth by averting long-term corticosteroid exposure.

Pharmacological Agent	Route Of Administration	Key Clinical Characteristics And Restrictions	Primary Limitations
Eltrombopag	Oral	Requires strict dietary compliance, specifically regarding calcium and dairy restrictions to prevent chelation.	Potential hepatotoxicity requiring rigorous liver function monitoring.
Romiplostim	Subcutaneous	Requires weekly injections, typically administered in a clinical setting.	Necessitates strict cold-chain maintenance; causes procedural pain and injection anxiety.
Avatrombopag	Oral	Once-daily dosing with minimal food interactions; no dietary dairy restrictions.	High procurement cost; recent market entry limits widespread real-world pediatric data.

Avatrombopag (Doptelet) represents the landmark 2025–2026 pharmacological advance in pediatric chronic ITP.
Received definitive FDA approval in July 2025 for pediatric patients aged 1 year and older with persistent or chronic ITP following prior therapy failure.
Surmounts the core limitations of older agents by offering convenient oral administration without eltrombopag’s strict dietary restrictions or hepatotoxicity concerns.

The global Phase 3b, randomized, placebo-controlled AVA-PED-301 trial evaluated 75 children (aged 1 to <18 years) with persistent/chronic ITP lasting over 6 months.
Demonstrated statistically significant superiority over placebo, achieving a durable platelet response (platelets $\geq$ 50 × 10⁹/L for $\geq$ 6 out of 8 weeks without rescue therapy) in 27.8% of patients versus 0% in the placebo cohort.
Overall platelet response reached 81.5% compared to 0% in the placebo group.
Exhibited rapid onset of action, with 55.6% of treated children achieving platelets $\geq$ 50 × 10⁹/L by day 8 of therapy.

Precision pediatric dosing is facilitated by age-specific formulations.
Children $\geq$ 6 years: Administered via oral tablets (starting dose typically 20 mg).
Children 1 to <6 years: Administered via sprinkle granules (starting dose 10 mg) mixed with soft food.

Avatrombopag is well-tolerated in the pediatric demographic with a favorable adverse event profile.
Most common adverse events are mild to moderate, including cough, nasopharyngitis, oropharyngeal pain, pyrexia, and localized viral infections.
Crucially, no new signals for drug-induced hepatotoxicity or unprovoked thrombosis emerged during the pediatric trials.

Hetrombopag: Currently approved for adult ITP in China; demonstrates a durable response rate of approximately 52% in Phase 3 adult trials, though dedicated pediatric efficacy data remains limited entering 2026.
Lusutrombopag: Explicitly not indicated for the management of chronic ITP.
TPO-RA Switching: Real-world pediatric cohorts highlight that switching between different TPO-RAs (e.g., from eltrombopag to avatrombopag) is a highly effective salvage strategy, rescuing 50% to 70% of patients who exhibit non-response or intolerance to their initial agent.

ASH 2019 Guidelines (2025 Draft Update): Recommends TPO-RAs (eltrombopag, romiplostim, and now avatrombopag) as the preferred second-line therapy over rituximab and splenectomy for children with non-life-threatening bleeding and poor quality of life unresponsive to first-line agents. Strongly endorses shared decision-making and supports switching TPO-RAs for insufficient response or adverse events.
AIEOP 2024 Italian Pediatric Guidelines: Supports early TPO-RA utilization to aggressively avoid surgical splenectomy. Broadens the definition of refractory ITP to encompass the failure of multiple therapeutic lines.

IAP Pediatric Hematology/Oncology (2023, Endorsed 2026): Aligns tightly with ASH recommendations. Welcomes newer oral agents like avatrombopag for improved convenience. Recommends clinical response monitoring at 4 to 8 weeks, explicitly discouraging routine annual bone marrow aspirations in favor of prioritizing bleeding risk and quality of life assessments.
MoHFW And ICMR Workflows (2025): The Standard Treatment Workflows (STWs) for Hematological Disorders formally endorse TPO-RAs as second-line standard of care under Ayushman Bharat and National Policy for Rare Diseases (NPRD) frameworks.
CDSCO Pathway: While older agents are available via Centres of Excellence, avatrombopag is progressing through the Central Drugs Standard Control Organization pathway post-FDA approval.

Pediatric hematologists must accurately identify chronic ITP progression (platelets <30 × 10⁹/L persisting >12 months accompanied by clinical bleeding or quality of life impact).
Initiation of avatrombopag allows for flexible dosing without the restrictive dairy avoidance counseling mandated by eltrombopag.
Clinical monitoring protocols require weekly complete blood counts during the initiation phase, transitioning to monthly platelet monitoring once therapeutic stability is achieved.
Upon achieving sustained clinical response, the pediatrician must carefully taper the TPO-RA to the absolute lowest effective dose required to prevent bleeding.
Long-term clinical surveillance remains mandatory to monitor for rare complications, including subclinical bone marrow reticulin fibrosis and thromboembolic events.

Economic Barriers: High procurement costs (avatrombopag therapy can cost between ₹50,000 to ₹1 Lakh monthly) severely limit widespread accessibility in Indian tier-2 cities.
Clinical Risks: Clinicians must remain vigilant for rare thrombosis risks (incidence <5%) and dangerous rebound thrombocytopenia immediately following abrupt drug discontinuation.
Future Trajectories: Ongoing Phase 3 pediatric trials for hetrombopag and investigations into combination therapies (e.g., TPO-RA paired with rituximab) aim to optimize remission rates.
Prognostic Modeling: Health economic modeling predicts that the integration of newer oral TPO-RAs will achieve sustained responses in 60% to 80% of children, permanently reducing pediatric splenectomy rates to under 5%.